Creating New Businesses
First written in FY2017. 3 of 8 entries say "Advanced", first in FY2019-Q3. Latest entry: FY2020-Q3.
88 other companies' latest entry also says "Advanced".
- FY2020-Q3AdvancedAnnual report
「In August 2019, our group acquired all shares of 藤永製薬株式会社 and entered the pharmaceutical manufacturing and marketing business as a third business, following the insurance pharmacy and BPO businesses. This enabled us to provide an end-to-end service covering the process from pharmaceutical manufacturing through delivery to patients. From the third quarter of the fiscal year, we began promoting sales of our own products through our group's insurance pharmacies to expand the business.」
After entering the third business, we began promoting sales of our own products through insurance pharmacies and presented an end-to-end service, from manufacturing through delivery to patients, as the direction for business expansion. - FY2020-Q2AdvancedAnnual report
「As an important business strategy for achieving its medium-term targets, the group planned the pharmaceutical manufacturing and sales business as a third business following the dispensing pharmacy and BPO businesses. As the first step toward entering and expanding this business, it acquired all shares of Fujinaga Pharmaceutical Co., Ltd. on 8 August 2019.」
For the pharmaceutical manufacturing and marketing business planned as the third business, we took the first step by acquiring all shares of 藤永製薬株式会社. - FY2020-Q1ReframedAnnual report
「As an important business strategy for achieving our medium-term targets, our group plans to make the pharmaceutical manufacturing and marketing business its third business, following the existing BPO business and centered on the insurance pharmacy business.」
The previous plans for creating a new business and a third core business were given concrete form as the pharmaceutical manufacturing and marketing business. - FY2019RaisedAnnual report
「In addition to growing the two core businesses, insurance pharmacies and BPO, we will advance plans for a new business with strong synergies with our existing businesses in order to create a third core business.」
We have positioned the creation of new businesses not merely as a growth initiative but as the creation of a third earnings pillar, and are advancing the plan. - FY2019-Q3AdvancedAnnual report
「As of 9 November 2018, we had brought SPLENDID into the group. SPLENDID provides medicommi, a medical information web media platform focused on accuracy under the supervision of physicians.」
SPLENDID, which provides the medicommi medical information web media platform, was brought into the group, expanding the new business domain. - FY2019-Q2RestatedAnnual report
「The Group aims to achieve further growth by accelerating the opening of dispensing pharmacies, creating new businesses and considering expansion into overseas markets.」
We continue to pursue a policy of further growth that includes creating new businesses. - FY2018-Q2RestatedAnnual report
「The Group aims to achieve further growth by accelerating the opening of dispensing pharmacies, creating new businesses and considering expansion into overseas markets.」
We continue to pursue the creation of new businesses as a policy for further growth, including after the transition to a holding company structure. - FY2017First statedAnnual report
「Against this backdrop, our group aims to strengthen its management platform for sustainable growth based on the following basic strategies: ① securing growth and profitability, ② pursuing group synergies, ③ organizational streamlining, ④ creating new businesses, and ⑤ Qol Group's human resources strategy.」
Creating new businesses is identified as a basic strategy for sustainable growth.